Ahmed Kamal

Dr. Ahmed Kamal

Faculty of Science - Suez University, Suez, As Suways, Egypt
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RNRoua Aref Nouh
Roua Aref Nouh
AKAhmed Kamal
Ahmed Kamal
AAAnwar Abdelnaser
Anwar Abdelnaser
Multiple sclerosis (MS) is a complicated condition in which the immune system attacks myelinated axons in the central nervous system (CNS), destroying both myelin and axons to varying degrees. Several environmental, genetic, and epigenetic factors influence the risk of developing the disease and how well it responds to treatment. Cannabinoids have recently sparked renewed interest in their therapeutic applications, with growing evidence for their role in symptom control in MS. Cannabinoids exert their roles through the endogenous cannabinoid (ECB) system, with some reports shedding light on the molecular biology of this system and lending credence to some anecdotal medical claims. The double nature of cannabinoids, which cause both positive and negative effects, comes from their actions on the same receptor. Several mechanisms have been adopted to evade this effect. However, there are still numerous limitations to using cannabinoids to treat MS patients. In this review, we will explore and discuss the molecular effect of cannabinoids on the ECB system, the various factors that affect the response to cannabinoids in the body, including the role of gene polymorphism and its relation to dosage, assessing the positive over the adverse effects of cannabinoids in MS, and finally, exploring the possible functional mechanism of cannabinoids in MS and the current and future progress of cannabinoid therapeutics.

26 May 2023 in Brain Research
Verified
Journal Article
Closed access
AKAhmed Kamal
Ahmed Kamal
MSMenha Swellam
Menha Swellam
NSNevin M. Shalaby
Nevin M. Shalaby
MDMarwa K. Darwish
Marwa K. Darwish
EEEslam M. El-Nahrery
Eslam M. El-Nahrery

7 February 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RNRoua Aref Nouh
Roua Aref Nouh
AKAhmed Kamal
Ahmed Kamal
OOOluwaseyi Oyewole
Oluwaseyi Oyewole
WAWalaa Abbas Adly Abbas
Walaa Abbas Adly Abbas
BABishoy Fayez Abib
Bishoy Fayez Abib
AAAnwar Abdelnaser
Anwar Abdelnaser
Multiple sclerosis is the predominant autoimmune disorder affecting the central nervous system in adolescents and adults. Specific treatments are categorized as disease-modifying, whereas others are symptomatic treatments to alleviate painful symptoms. Currently, no singular conventional therapy is universally effective for all patients across all stages of the illness. Nevertheless, cannabinoids exhibit significant promise in their capacity for neuroprotection, anti-inflammation, and immunosuppression. This review will examine the traditional treatment for multiple sclerosis, the increasing interest in using cannabis as a treatment method, its role in protecting the nervous system and regulating the immune system, commercially available therapeutic cannabinoids, and the emerging use of cannabis in nanomedicine. In conclusion, cannabinoids exhibit potential as a disease-modifying treatment rather than merely symptomatic relief. However, further research is necessary to unveil their role and establish the safety and advancements in nano-cannabinoid medicine, offering the potential for reduced toxicity and fewer adverse effects, thereby maximizing the benefits of cannabinoids.

7 April 2024 in Journal of Translational Genetics and Genomics
Verified
Journal Article
Open access
PDF file
AKAhmed Kamal
Ahmed Kamal
MSMenha Swellam
Menha Swellam
NSNevin M. Shalaby
Nevin M. Shalaby
MDMarwa K. Darwish
Marwa K. Darwish
EEEslam M. El-Nahrery
Eslam M. El-Nahrery
Long non-coding RNAs (lncRNAs) are a class of RNA transcripts that are long (i.e., more than 200 nucleotides) and not translated into proteins. They have recently emerged as potential treatment targets for numerous disorders due to their involvement in multiple cellular functions such as gene regulation, epigenetic modulation, and chromatin organization. This review highlights the current state of lncRNA-based therapeutics, the potential of lncRNAs as drug targets for treating human diseases, the various strategies and types of RNA-based therapeutics, and the complications of developing lncRNA-based drugs. We conclude that lncRNA-based therapeutics represent a promising class of drugs that can potentially treat various human diseases and that further research is needed to fully realize their therapeutic potential.

31 January 2025 in INNOSC Theranostics and Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
AKAhmed Kamal
Ahmed Kamal
MSMenha Swellam
Menha Swellam
NSNevin M. Shalaby
Nevin M. Shalaby
MDMarwa K. Darwish
Marwa K. Darwish
EEEslam El-Nahrery
Eslam El-Nahrery
Multiple sclerosis (MS) is a prevalent neurological disorder affecting the central nervous system, with a global incidence exceeding 2.5 million cases. Brain-derived neurotrophic factor-antisense (BDNF-AS), a long non-coding RNA, has been identified as a factor that negatively influences the expression of brain-derived neurotrophic factor, a neurotrophin protein that exhibits heightened expression within actively demyelinating lesions in MS. This study aims to assess the relative expression of BDNF-AS across all MS subtypes, evaluate its diagnostic accuracy, and explore correlations between BDNF-AS expression and disease parameters. Quantitative real-time polymerase chain reaction was employed to quantify the expression levels of BDNF-AS in the serum samples of 54 individuals diagnosed with various types of MS and 20 healthy controls. Statistical analyses were performed to assess the correlation and diagnostic efficacy of BDNF-AS expression levels. The expression of BDNF-AS was markedly reduced in individuals with MS compared to the control group (P < 0.01). Notably, the highest expression levels were observed in patients diagnosed with secondary progressive MS. Using a defined cutoff value of 0.31, and the findings suggest that BDNF-AS expression in serum has notable potential as a specific and sensitive diagnostic marker for MS. In conclusion, this study provides a comprehensive evaluation of BDNF-AS across all MS subtypes, highlighting its diagnostic accuracy and the association between elevated BDNF-AS expression and disease progression in secondary progressive MS. Further research is needed to validate these results.